이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Celularity 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Bob Hariri

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	3yrs
CEO 소유권	13.1%
경영진 평균 재임 기간	2yrs
이사회 평균 재임 기간	3yrs

최근 관리 업데이트

Recent updates

Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 80%

Feb 14

News Flash: Analysts Just Made A Massive Upgrade To Their Celularity Inc. (NASDAQ:CELU) Forecasts

Dec 14

Celularity: Celgene Spin-Off Developing Allogeneic Therapies

Sep 06

CEO 보상 분석

Bob Hariri 의 보수는 Celularity 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2023	n/a	n/a	-US$181m
Jun 30 2023	n/a	n/a	-US$83m
Mar 31 2023	n/a	n/a	US$13m
Dec 31 2022	US$5m	US$1m	US$14m
Sep 30 2022	n/a	n/a	-US$14m
Jun 30 2022	n/a	n/a	US$31m
Mar 31 2022	n/a	n/a	-US$81m
Dec 31 2021	US$22m	US$1m	-US$100m
Sep 30 2021	n/a	n/a	-US$92m
Jun 30 2021	n/a	n/a	-US$188m
Mar 31 2021	n/a	n/a	-US$260m
Dec 31 2020	US$3m	US$1m	-US$208m

보상 대 시장: US 시장에서 비슷한 규모의 회사에 비해 Bob 의 총 보상이 합리적인지 여부를 입증하기에는 데이터가 부족합니다.

보상과 수익: Bob 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Bob Hariri (65 yo)

3yrs

테뉴어

US$5,242,529

보상

Dr. Robert Joseph Hariri, also known as Bob, M.D., Ph.D. is a Co-Founder of Human Longevity, Inc. and serves as President of Human Longevity Cellular Therapeutics. He serves as Medical Advisor at Beyond Im...

리더십 팀

이름	위치	테뉴어	보상	소유권
Robert Hariri	Founder	3yrs	US$5.24m	13.07% $ 8.7m
David Beers	Chief Financial Officer	3yrs	US$1.71m	0.034% $ 22.4k
John Haines	Senior EVP	1.8yrs	US$2.50m	0.0049% $ 3.2k
Ramji Krishnan	Chief Technology Officer	1.1yrs	데이터 없음	데이터 없음
Carlos Ramirez	SVP of Investor Relations	no data	데이터 없음	데이터 없음
Kyle Fletcher	Executive VP	2yrs	데이터 없음	0.0034% $ 2.2k
Stephen Brigido	President of Degenerative Diseases	3yrs	데이터 없음	0.0025% $ 1.7k
Adrian Kilcoyne	Executive VP	1.8yrs	데이터 없음	0.52% $ 341.2k
Sharmila Koppisetti	Senior Vice President of Clinical Dev. Immunology & Drug Safety	2.5yrs	데이터 없음	데이터 없음
Tim Wilk	Senior Vice President of Technical Operations	1.1yrs	데이터 없음	데이터 없음
David Lemus	Treasurer	no data	데이터 없음	데이터 없음
Timothy Smith	Secretary	no data	데이터 없음	데이터 없음

2.0yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: CELU 의 관리팀은 경험 ( 2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Robert Hariri	Founder	3yrs	US$5.24m	13.07% $ 8.7m
Diane Parks	Independent Director	2.1yrs	US$627.68k	0.017% $ 11.0k
Louis Weiner	Member of Scientific Advisory Board	2.5yrs	데이터 없음	데이터 없음
Dean Kehler	Independent Director	6.5yrs	US$373.00k	0.85% $ 561.0k
Peter Diamandis	Independent Director	3yrs	US$353.50k	0.51% $ 336.6k
Marc Mazur	Independent Director	5.2yrs	US$371.00k	0.039% $ 25.9k
Geoffrey Shiu Ling	Director	less than a year	데이터 없음	데이터 없음
Darren Sigal	Co-Chairman of Scientific Advisory Board	no data	데이터 없음	데이터 없음

3.0yrs

평균 재임 기간

67yo

평균 연령

경험이 풍부한 이사회: CELU 의 이사회는 경험(평균 재직 기간 3 년)으로 간주됩니다.

Celularity 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

High number of new and inexperienced directors

Celularity Inc. Announces Resignation of Robin L. Smith, MD, from Board of Directors

Lim Kok Thay Notifies Celularity Inc. of His Intention to Resign as a Member of the Board and All Committees

Celularity Inc. Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors

High number of new and inexperienced directors

Independent Director exercised options to buy US$822k worth of stock.

Recent updates

Celularity Presents Data of the Effect of Its T-Cell Platform on Multiple Hematological and Solid Tumors At the American Society of Clinical Oncology (Asco) Annual Meeting

Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Celularity Inc. announced delayed 10-Q filing

Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Celularity Inc. announced delayed annual 10-K filing

Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L

Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 80%

High number of new and inexperienced directors

Celularity Inc. Provides Sales Guidance for the First Quarter and Full Year 2024

Genting Berhad Engages in Discussions with Celularity Inc

Celularity Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Celularity Inc. Announces Resignation of Robin L. Smith, MD, from Board of Directors

Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Celularity Inc. announced delayed 10-Q filing

Lim Kok Thay Notifies Celularity Inc. of His Intention to Resign as a Member of the Board and All Committees

Celularity Inc. Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Celularity Inc. to Present Data from a New Product Technology in Development for Orthopedic Applications at 7th International Conference on Orthopedics

New major risk - Share price stability

Celularity Inc. Announces Results from Exploratory Analysis of Phase 1 Data Evaluating Alterations in Gene and Protein Signatures Associated with Inflammation and Fistula Formation in Patients with Crohn's Disease

Celularity Inc. announced delayed 10-Q filing

Price target decreased by 24% to US$8.63

Consensus revenue estimates decrease by 36%, EPS upgraded

Independent Director exercised options to buy US$822k worth of stock.

Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (Ctw)

Celularity Inc. Announces the Suspends of Robert Hariri as Chairman

Price target decreased by 12% to US$9.50

Celularity Inc. Announces in A Preclinical in Vivo Study of Placental Extracellular Matrix

Celularity Inc.'s Placental-Derived Allogeneic Cell Therapy Provides Clinically Meaningful Benefit and Durable Biological Effect in Patients with Moderate to Severe Crohn's Disease in Phase 1, Phase 1b/2a and Phase 1b Studies

Celularity Inc. Appoints Paul Graves as Chief Communications Officer

Consensus forecasts updated

Celularity Inc. Announces Halal Certification of Its Advanced Cellular Therapeutics, Biomaterial Products and Business Model

Founder recently bought US$70k worth of stock

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: US$0.034 (vs US$0.47 in 3Q 2021)

Imugene’s on CARlytics Combination with Celularity’s Placental-derived off-the-shelf Allogeneic CYCART-19 T Cells Preclinical Data Presented at SITC Annual Meeting

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Celularity Promotes Two Executives in Executive Leadership Team

Celularity Appoints Adrian Kilcoyne as Executive Vice President, Chief Medical Officer and Head of Global Affairs, Patient Safety and Patient Affairs

Celularity appoints Adrian Kilcoyne as chief medical officer

Celularity Inc. Publishes New Data in Frontiers in Immunology Demonstrating Placental-Derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-Infected Cells in Vitro

Celularity Inc. Announces Resignation of Andrew L. Pecora, M.D., F.A.C.P., as Company’s President Effective as of August 31, 2022

Celularity falls after announcing fund raising deal

Investor sentiment deteriorated over the past week

High number of new and inexperienced directors

Celularity falls 10% on deal for $150M common stock offering

Founder exercised options to buy US$343k worth of stock.

Price target decreased to US$10.60

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Celularity Inc. Announces Treatment of First Patient in Phase 1/2a Clinical Trial for NK Cell Therapy CYNK-101, in Development for the First-Line Treatment of Advanced HER2 Positive Gastric and Gastroesophageal Junction (G/GEJ) Cancers

Celularity begins phase 1/2a trial for cell therapy CYNK-101 to treat cancers

Celularity Inc. Announces the Resignation of Andrew L. Pecora as President, Effective from August 31, 2022

Price target increased to US$11.80

Celularity Inc. Announces Board Changes

Celularity Inc. Appoints Diane Parks to Board of Directors

Celularity Inc. announced that it has received $30.000007 million in funding

Consensus estimates of losses per share improve by 34%

Celularity Inc. announced that it expects to receive $30.000007 million in funding

First quarter 2022 earnings: Revenues exceed analyst expectations

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers